Back
Royal Caribbean Group Vs. Ultragenyx Pharmaceutical Industry Stock Comparison
Buy
69
RCL
Royal Caribbean Group
Last Price:
142.01
Seasonality Move:
3.33%
Sell
38
RARE
Ultragenyx Pharmaceutical
Last Price:
44.29
Seasonality Move:
10.8%
Buy
69
Royal Caribbean Group (RCL)
is a Buy
Is Royal Caribbean Group a Buy, Sell or Hold?
- The current Royal Caribbean Group [RCL] share price is $140.59. The Score for RCL is 69, which is 38% above its historic median score of 50, and infers lower risk than normal.
- RCL is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
38
Ultragenyx Pharmaceutical (RARE)
is a Sell
Is Ultragenyx Pharmaceutical a Buy, Sell or Hold?
- The current Ultragenyx Pharmaceutical [RARE] share price is $44.24. The Score for RARE is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.
- RARE is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
RCL Stock Price Chart
What is Royal Caribbean Group's stock price today?
-
The Royal Caribbean Group share price today is $140.59
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and RCL is experiencing buying pressure, which is a positive indicator for future bullish movement.
RARE Stock Price Chart
What is Ultragenyx Pharmaceutical's stock price today?
-
The Ultragenyx Pharmaceutical share price today is $44.24
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and RARE is experiencing slight buying pressure.
RCL Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.4 | Buy |
| Relative Strength Index (14 RSI): | 64.91 | Buy |
| Chaikin Money Flow: | 2364054 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (130 - 138.9) | Buy |
| Bollinger Bands (100): | (119.56 - 132.88) | Buy |
RARE Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -1.09 | Sell |
| Relative Strength Index (14 RSI): | 43.92 | Sell |
| Chaikin Money Flow: | 101540 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (43.49 - 48.87) | Sell |
| Bollinger Bands (100): | (43.62 - 49.46) | Sell |
RCL Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 133.53 | Buy |
| 20-day SMA: | 133.67 | Buy |
| 50-day SMA: | 129.77 | Buy |
| 200-day SMA: | 111.54 | Buy |
| 8-day EMA: | 135.26 | Buy |
| 20-day EMA: | 133.47 | Buy |
| 50-day EMA: | 130.3 | Buy |
| 200-day EMA: | 112.73 | Buy |
RARE Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 43.87 | Buy |
| 20-day SMA: | 46.21 | Sell |
| 50-day SMA: | 47.79 | Sell |
| 200-day SMA: | 42.13 | Buy |
| 8-day EMA: | 44.35 | Sell |
| 20-day EMA: | 45.49 | Sell |
| 50-day EMA: | 46.38 | Sell |
| 200-day EMA: | 44.57 | Sell |
Royal Caribbean Group Earnings Growth & RCL Earnings Dates
- Analysts estimate an earnings increase this quarter of $1.30 per share, a decrease next quarter of $1.54 per share, an increase this year of $4.13 per share, and an increase next year of $1.54 per share.
Ultragenyx Pharmaceutical Earnings Growth & RARE Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.39 per share, an increase next quarter of $0.02 per share, an increase this year of $1.08 per share, and an increase next year of $0.95 per share.
Royal Caribbean Group Technical Analysis
| Apr 15 | Apr 16 | Apr 17 | Apr 18 | Apr 19 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | Apr 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 15 | 16 | 17 | 18 | 19 | 22 | 23 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Ultragenyx Pharmaceutical Technical Analysis
| Apr 15 | Apr 16 | Apr 17 | Apr 18 | Apr 19 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | Apr 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 15 | 16 | 17 | 18 | 19 | 22 | 23 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||